IDH Releases Q1 2023 Financial Results
(Cairo and London) — Integrated Diagnostics Holdings (“IDH,” “the Group,” or “the Company”), a leading consumer healthcare company with operations in Egypt, Jordan, Nigeria and Sudan, released today its reviewed financial statements and operational performance for the quarter ended 31 March 2023, booking revenue of EGP 915 million, 22% below revenues reported in the first quarter of the previous year when Covid-19-related testing had significantly boosted the consolidated figure. Excluding the contribution made by Covid-19-related testing in the comparable three months of 2022, the Group’s conventional revenues recorded an impressive 43% year-on-year expansion supported by a 12% year-on-year increase in conventional test volumes and a 27% year-on-year increase in average revenue per conventional test for the quarter. IDH recorded a net profit of EGP 168 million, declining 46% from Q1 2022 and with an associated margin of 18%.